Mirtazapina Tevagen (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Tevagen, is a tetracyclic antidepressant presented as a tablet for buccal, oral, sublingual use. It treats major depressive disorder in adult patients.

GNH USA supplies Mirtazapina Tevagen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is indicated for depressive disorders that involve serotonergic and noradrenergic pathways. - Major depressive disorder: reduces depressive symptoms and improves mood in adults. - Persistent depressive disorder (dysthymia): helps alleviate chronic low‑grade depressive mood. - Depression with anxiety features: may improve both mood and anxiety components.

Mirtazapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or severe leukopenia - Seizures - Severe hypotension - Hepatic dysfunction - Suicidal thoughts or behavior - Stevens‑Johnson syndrome

When prescribing or dispensing mirtazapine, consider the following safety measures. - Monitor weight: patients may experience significant weight gain. - Assess hepatic function: dose adjustment may be needed in liver impairment. - Evaluate for suicidal ideation: especially during early treatment. - Caution in elderly: increased risk of sedation and falls. - Avoid abrupt discontinuation: taper to reduce withdrawal symptoms. - Store below 25°C: keep in the original pack, protect from moisture.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Potent CYP3A4 inhibitors (e.g., ketoconazole): may increase mirtazapine plasma levels. - CNS depressants (e.g., benzodiazepines, alcohol): additive sedation.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., codeine, tamoxifen): altered metabolism. - Anticholinergic agents: may exacerbate dry mouth and constipation. - Warfarin: potential effect on INR, monitor coagulation parameters.